Indeed, we focused our attention on representing a potential model for a delivery system by genetically engineering OMVs equipped with GALA in which multiple parts would act in concert to accomplish an effectual and specific delivery platform to be used in EGFR-positive breast cancer therapy. This evidence concerns the gene EGFR and breast carcinoma.